List of Pennsaid drug patents

Pennsaid is owned by Horizon.

Pennsaid contains Diclofenac Sodium.

Pennsaid has a total of 19 drug patents out of which 0 drug patents have expired.

Pennsaid was authorised for market use on 16 January, 2014.

Pennsaid is available in solution;topical dosage forms.

Pennsaid can be used as use of topical diclofenac on the knee and a second topical prescription medication on the same knee, use of topical diclofenac sodium for treating pain, use of topical diclofenac on a joint for treating osteoarthritis, combination use of topical diclofenac on the knee and administration of an oral nsaid., use of topical diclofenac for treating pain, combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant.

The generics of Pennsaid are possible to be released after 09 August, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220784 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9339552 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9539335 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8563613 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8871809 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9101591 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9066913 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9339551 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9168304 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9132110 HORIZON Treatment of pain with topical diclofenac
Oct, 2027

(4 years from now)

US9168305 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8252838 HORIZON Diclofenac topical formulation
Apr, 2028

(4 years from now)

US8741956 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8618164 HORIZON Treatment of pain with topical diclofenac compounds
Jul, 2029

(6 years from now)

US9370501 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8217078 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US9415029 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US9375412 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8546450 HORIZON Treatment of pain with topical diclofenac compounds
Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 16 January, 2014

Treatment: Use of topical diclofenac for treating pain; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Combination use of topical diclofenac...

Dosage: SOLUTION;TOPICAL

How can I launch a generic of PENNSAID before it's patent expiration?
More Information on Dosage

PENNSAID family patents

31

United States

2

China

2

European Union

1

Australia

1

Brazil

1

Hong Kong

1

Denmark

1

South Africa

1

New Zealand

1

Canada

1

Russia

1

Israel

1

Mexico

1

Japan

Pennsaid is owned by Nuvo Pharms Inc.

Pennsaid contains Diclofenac Sodium.

Pennsaid has a total of 4 drug patents out of which 0 drug patents have expired.

Pennsaid was authorised for market use on 04 November, 2009.

Pennsaid is available in solution;topical dosage forms.

Pennsaid can be used as combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant, use of topical diclofenac on the knee and a second topical medication on the same knee, combination use of topical diclofenac on the knee and administration of an oral nsaid., use of topical diclofenac on the knee and a second topical prescription medication on the same knee.

The generics of Pennsaid are possible to be released after 09 August, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741956 NUVO PHARMS INC Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8618164 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds
Jul, 2029

(6 years from now)

US8217078 NUVO PHARMS INC Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8546450 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds
Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 04 November, 2009

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topi...

Dosage: SOLUTION;TOPICAL

How can I launch a generic of PENNSAID before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic